Frank Kelly, Jr. Appointed to InVasc Therapeutics Board of Directors

Frank Kelly, Jr. Appointed to InVasc Therapeutics Board of Directors

ATLANTA--(BUSINESS WIRE)--Sep 20, 2010 - InVasc Therapeutics, Inc., a biopharmaceutical company focused on chronic kidney and cardiometabolic diseases, announced today the appointment of Frank Kelly, Jr. to its Board of Directors. Mr. Kelly brings forty years of experience in finance, marketing and operations to InVasc.

"We are very pleased to welcome Mr. Kelly to our Board," stated William Johnston, Ph.D., Chief Executive Officer of InVasc. "Frank's experience was predominately with The Coca-Cola Company where he held executive rolls both domestically and globally. With this strong background, Frank will also chair our Audit Committee."

Mr. Kelly joined The Coca-Cola Company in 1970 after completing an MBA at Harvard University. At the time of his early retirement from Coke in 1999, he was Corporate Vice President, and President and CEO of the Coca-Cola Nestlé Refreshments joint venture. For an interim period in his career, he spent time in Japan with Pepsico International as CEO of PepsiCo (Japan) Company, Ltd. He then moved back to The Coca-Cola Company where he oversaw the positioning of Coke in Korea in preparation for the Olympics. After leaving The Coca-Cola Company Frank formed MFK Global, Inc., a diversified strategic marketing and consulting firm. Frank serves on multiple boards including the Arthritis Foundation.

About InVasc

InVasc Therapeutics, Inc., headquartered in Tucker, Georgia, is a biopharmaceutical company developing drugs to mitigate risks associated with chronic kidney and cardiometabolic diseases. Cardiovascular and metabolic diseases such as diabetes, hypertension, stroke and dyslipidemia are the leading causes of morbidity and mortality worldwide. The Company plans to file an IND early next year for INV-144 targeting slowing the progression of chronic kidney disease in hypertensive diabetic patients. In a previous human clinical trial, a sister compound (INV-141) demonstrated statistical significance in the reduction of proteinuria in the same patient population. InVasc's pipeline development is supported by two recent SBIR grants.


Contact: InVasc Therapeutics, Inc.
William D. Johnston, Ph.D., 678-736-5903
Chief Executive Officer
[email protected]